Symetis has developed a minimally invasive heart valve replacement solution, the Symetis Acurate TA™ system, based on proprietary geometry and delivery technology. The product received CE Mark in September 2011 and is well positioned to target the ca. USD 2 billion transcatheter aortic valve implantation (TAVI) market worldwide. The Acurate TA™ system offers unique self-positioning design, resulting in unmatched positioning tolerance and ease of use for the physician. The company is based in Lausanne, Switzerland.

Recent News

March 30, 2017
Symetis and Boston Scientific reach USD 435 million purchase agreement

March 20, 2017
MedTech Company Launches Large €55M IPO for Artificial Heart Valves

March 20, 2017
Symetis launches its IPO on Euronext Paris

September 1, 2015
Symetis announces intention to float on SIX Swiss Exchange

April 23, 2015
L’étoile montante des medtech suisses

September 12, 2014
Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations

October 28, 2013
Symetis Announces a Symbolic Milestone - the 1000th Patient Implanted with ACURATE TA™

September 26, 2013
Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI

August 12, 2013
Symetis announces successful, first time implantation of i ts ACURATE TA™ and ACURATE TF™ TAVI systems in Japan

April 3, 2013
Symetis' ACURATE TA(TM) Confirms Superior Results

October 22, 2012
Symetis ACURATE TF™ FIM Trial Completed

September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

October 7, 2010
Symetis closes CHF 25 million financing led by Endeavour Vision and NBGI Ventures, Eric Milledge appointed Chairman of the Board


Company Info
Country: Switzerland
Industry:    Biotech
Sector: medical technology
Status: Unrealized
Vehicle: Endeavour II LP

Key persons
 CEO: Jacques Essinger

Company website

Endeavour Vision Team
Damien Tappy
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions